Gastrointestinal Tumors Clinical Trial
Official title:
A Multicenter, Open-label, Parallel Controlled, Prospective Cohort Study Evaluating Immunonutrition on the Improvement of Postoperative Adjuvant Chemotherapy Related Adverse Reactions in Patients With Gastrointestinal Tumors
Evaluate the effects of Suyusu (immunonutrition) in postoperative adjuvant chemotherapy for gastrointestinal cancer patients. The main endpoint of the study was the incidence of chemotherapy related adverse reactions (including bone marrow suppression, nausea and vomiting, diarrhea, and mucositis) in patients after two cycles of chemotherapy. The secondary endpoint indicators were: quality of life score (EORTC-QLQ-C30), nutritional risk score (PG-SGA, NRS2002), nutritional assessment indicators, changes in immune microenvironment, analysis of psychological status, survival time (1-year progression free survival rate), treatment tolerance (dose intensity, rate of treatment interruption, delay), etc.
n/a
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT05922358 -
Phase II Study of Reuse of Oxaliplatin Hypersensitivity in Gastrointestinal Tumors
|
Phase 2 | |
Recruiting |
NCT06152757 -
BGT007H Cells for the Treatment of Recurrent/Refractory Gastrointestinal Tumors
|
Early Phase 1 | |
Terminated |
NCT04171141 -
Study to Test the Safety and Tolerability of PF-07062119 in Patients With Selected Advanced or Metastatic Gastrointestinal Tumors.
|
Phase 1 | |
Completed |
NCT01552291 -
The Impact of Preoperative Oral Glutamine Intake on the Immunocompetence and Outcomes of Malnourished Patients Undergoing Major Abdominal Surgery Due to Malignancies
|
Phase 4 | |
Active, not recruiting |
NCT03833700 -
A Study of E7386 in Participants With Advanced Solid Tumor Including Colorectal Cancer (CRC)
|
Phase 1 | |
Completed |
NCT01640665 -
Pilot Study of Sorafenib and Bi-weekly Capecitabine in Patients With Advanced Breast and Gastrointestinal Tumors
|
Phase 1 | |
Recruiting |
NCT04629326 -
PD-L1 Targeting Molecular Imaging of Solid Tumors
|
N/A | |
Recruiting |
NCT05981235 -
Phase 1 Trial of AZD6422 in CLDN18.2+ GI Tumors
|
Phase 1 | |
Recruiting |
NCT05262335 -
Anlotinib Plus Chemotherapy as First-line Therapy for Gastrointestinal Tumor Patients With Unresectable Liver Metastasis (ALTER-G-001)
|
Phase 2 | |
Terminated |
NCT01648465 -
Study of Everolimus Treatment in Newly-diagnosed Patients With Advanced Gastrointestinal Neuroendocrine Tumors
|
Phase 2 | |
Not yet recruiting |
NCT06263205 -
Wound Management Following Gl Tumor Surgery: Comparing Outcomes of Dressing Changes Versus Non-Dressing Techniques
|
N/A |